SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly)
PFE 25.44+1.5%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Henry Niman who wrote (1333)1/21/1999 6:00:00 AM
From: Anthony Wong  Read Replies (1) of 1722
 
[Merck's] Drug reduces vomiting in cancer patients - study
Thursday January 21, 1:46 am Eastern Time

By Gene Emery

BOSTON, Jan 20 (Reuters) - An experimental drug being developed by Merck & Co. Inc. (NYSE:MRK - news) dramatically reduces nausea and vomiting in cancer patients being treated with cisplatin, according to a study of 159 patients in Thursday's New England Journal of Medicine.

Cisplatin is a powerful and widely-used anti-cancer drug, but it often sparks vomiting within 24 hours, followed by a second wave of vomiting within two to five days. The experimental drug is known by the laboratory designation L-754,030.

In the study, a team led by Dr. Rudolph Navari of the Simon-Williamson Clinic in Birmingham, Ala., gave all volunteers conventional anti-vomiting drugs during their treatment with cisplatin. In
addition, one third of the patients got a placebo while two thirds were given L-754,030.

Within 24 hours, 33 percent of the placebo patients had vomited compared with 7 percent of the L-754,030 recipients.

The drug was even more effective when it came to preventing the body's delayed reaction to cisplatin. While 67 percent of the placebo recipients vomited in that phase, the rate was less than 22 percent among people who got the experimental drug.

L-754,030 produced no obvious side effects, said the Navari team, which included several Merck researchers.

biz.yahoo.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News